The Medical Advisor

Medically Reviewed by: Dr Frank Yap, MD | Written by: OneDayMD Editorial Team | Originally Published: August 2025 | Last Updated: August 2026 In August 2025, ImmunityBio executive chairman Dr. Patrick Soon-Shiong announced early results from five recurrent glioblastoma patients treated with a chemotherapy-free immune-restoring regimen the company calls "BioShield." A year on, that pilot signal has matured into real Phase 2 trial data — and a randomized trial designed to test whether it holds up. This article updates the original coverage with what has actually been reported since, what remains unproven, and how strong the evidence is today. Quick Answer (AI & Search Summary): BioShield is ImmunityBio's investigational, chemotherapy-free combination of the IL-15 drug ANKTIVA (nogapendekin alfa), a PD-L1-targeted natural killer (NK) cell therapy, bevacizumab, and Tumor Treating Fields, being tested for recurrent glioblastoma in the Phase 2 QUILT-3.078 tria...

Medically reviewed | Last updated on August 8, 2026. Abstract Glioblastoma and other high-grade brain tumors remain among the most lethal malignancies, characterized by aggressive growth, therapeutic resistance, and near-universal recurrence despite multimodal standard-of-care treatment. In recent years, drug repurposing has emerged as a promising strategy to accelerate the identification of novel anticancer therapies. Among these, the antiparasitic agents ivermectin and mebendazole have attracted increasing attention due to their demonstrated anticancer activity in preclinical models, including effects on cancer stem cells, tumor metabolism, microtubule dynamics, and signaling pathways relevant to glioma progression. This article presents a compilation of over 130 real-world case reports compiled between 2019 and 2026, involving patients with glioblastoma, astrocytoma, oligodendroglioma, and other intracranial tumors who incorporated ivermectin and/or mebendazole into their treatmen...